GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Proto Script Pharmaceutical Corp (OTCPK:PSCR) » Definitions » EV-to-Revenue

Proto Script Pharmaceutical (Proto Script Pharmaceutical) EV-to-Revenue : 0.00 (As of May. 25, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Proto Script Pharmaceutical EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Proto Script Pharmaceutical's enterprise value is $0.00 Mil. Proto Script Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Sep. 2017 was $0.60 Mil. Therefore, Proto Script Pharmaceutical's EV-to-Revenue for today is 0.00.

The historical rank and industry rank for Proto Script Pharmaceutical's EV-to-Revenue or its related term are showing as below:

PSCR's EV-to-Revenue is not ranked *
in the Business Services industry.
Industry Median: 1.21
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Proto Script Pharmaceutical's stock price is $0.0002. Proto Script Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2017 was $0.01. Therefore, Proto Script Pharmaceutical's PS Ratio for today is 0.03.


Proto Script Pharmaceutical EV-to-Revenue Historical Data

The historical data trend for Proto Script Pharmaceutical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proto Script Pharmaceutical EV-to-Revenue Chart

Proto Script Pharmaceutical Annual Data
Trend May12 May13 May14 May15 May16
EV-to-Revenue
- - - - -

Proto Script Pharmaceutical Quarterly Data
Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Sep16 Dec16 Mar17 Jun17 Sep17
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 267.66 696.63 5.07 3.90 3.88

Competitive Comparison of Proto Script Pharmaceutical's EV-to-Revenue

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proto Script Pharmaceutical's EV-to-Revenue Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's EV-to-Revenue falls into.



Proto Script Pharmaceutical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Proto Script Pharmaceutical's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.000/0.604
=0.00

Proto Script Pharmaceutical's current Enterprise Value is $0.00 Mil.
Proto Script Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proto Script Pharmaceutical  (OTCPK:PSCR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Proto Script Pharmaceutical's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0002/0.008
=0.03

Proto Script Pharmaceutical's share price for today is $0.0002.
Proto Script Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proto Script Pharmaceutical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Headlines

No Headlines